Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study
Open Access
- 20 November 2017
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (11) , 2465
Abstract
This is the first study investigating the clinical relevance of 5-hydroxymethylcytosine (5hmC) in genomic DNA from white blood cells (WBC) in the context of prostate cancer (PCa) and other prostate pathologies. Using an enzyme-linked immunosorbent assay, we identified significantly different distributions of patients with low and elevated 5hmC content in WBC DNA across controls and patients with prostate cancer (PCa), atypical small acinar proliferation (ASAP), and benign prostatic hyperplasia (BPH). The measured values were within the normal range for most PCa patients, while the latter category was predominant for ASAP. We observed a wider heterogeneity in 5hmC content in all of the prostate pathologies analyzed when compared to the healthy age-matched controls. When compared to blood levels of prostate-specific antigen (PSA), this 5hmC-based biomarker had a lower performance in PCa detection than the use of a PSA cut-off of 2.5 nanograms per milliliter (ng/mL). Above this threshold, however, it delineated almost three quarters of PCa patients from controls and patients with other prostate pathologies. Overall, genome-wide 5hmC content of WBC DNA appears to be applicable for detecting non-cancerous prostate diseases, rather than PCa. Our results also suggest a potential clinical usefulness of complementing PSA as a PCa marker by the addition of a set of hydroxymethylation markers in the blood, but further studies are necessary to confirm these findings.Keywords
Funding Information
- Romanian National Authority for Scientific Research and Innovation, CNCS-UEFISCDI, Research Council (project number PN-II-RU-TE-2014-4-2854)
This publication has 59 references indexed in Scilit:
- Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patternsBMC Cancer, 2017
- Technical advances in global DNA methylation analysis in human cancersJournal of Biological Engineering, 2017
- The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancerExpert Review of Molecular Diagnostics, 2016
- Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1Oncotarget, 2016
- Effects of particulate matter exposure on blood 5-hydroxymethylation: results from the Beijing truck driver air pollution studyEpigenetics, 2015
- Association of Global DNA Methylation and Global DNA Hydroxymethylation with Metals and Other Exposures in Human Blood DNA SamplesEnvironmental Health Perspectives, 2014
- Epigenetic biomarkers in prostate cancer: Current and future usesCancer Letters, 2014
- Prostate Cancer Early DetectionJournal of the National Comprehensive Cancer Network, 2010
- Considerations in determining sample size for pilot studiesResearch in Nursing & Health, 2008
- BPH: epidemiology and comorbidities.2006